<?xml version="1.0" encoding="UTF-8"?>
<p>Lopinavir and ritonavir (LPV/r) is considered a promising treatment option for COVID-19 based on the 2003 SARS treatment experience.
 <xref rid="B2" ref-type="bibr">2</xref>
 <xref rid="B3" ref-type="bibr">3</xref> However, care should be taken when administering because there are no or little clinical evidence for the new virus, SARS-CoV-2. I have treated with LPV/r as an antiviral agent in patients with pneumonia caused by COVID-19, but the disease course has not improved dramatically.
 <xref rid="B4" ref-type="bibr">4</xref> Fortunately, the patient did not develop acute respiratory failure, but it was not clear whether it was an effect of antiviral drug.
</p>
